Erratum: miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma (Genes & Development (2015) 29 (732–745) DOI: 10.1101/gad.257394.114);MiR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma

Genes and Development

Volumn 29, Issue 7, 2015, Pages 732-745

  Kouri, Fotini M ^a   Hurley, Lisa A ^a   Daniel, Weston L ^b   Day, Emily S ^c,d   Hua, Youjia ^a   Hao, Liangliang ^c,d   Peng, Chian Yu ^a   Merkel, Timothy J ^c,d   Queisser, Markus A ^c   Ritner, Carissa ^a   Zhang, Hailei ^e,f,g,h   David James, C ^a   Sznajder, Jacob I ^c   Chin, Lynda ^e,f,g,h   Giljohann, David A ^b   Kessler, John A ^a   Peter, Marcus E ^a   Mirkin, Chad A ^c,d   Stegh, Alexander H ^a,c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AuraSense Therapeutics   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bcl2L12; c Met; Glioblastoma; HIF2A; miR 182; Nanotechnology; Spherical nucleic acids

Indexed keywords

BCL2 LIKE12 PROTEIN; CASPASE 3; CASPASE 7; DOXORUBICIN; GOLD NANOPARTICLE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMATINIB; MICRORNA 182; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL 2; PROTEIN P53; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCL2L12 PROTEIN, HUMAN; MICRORNA; MIRN182 MICRORNA, HUMAN; MUSCLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CELL SHAPE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILVER STAINING; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SCID MOUSE; SURVIVAL; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MICE, SCID; MICRORNAS; MUSCLE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS;

EID: 84926392353     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.351832.124     Document Type: Erratum

References (57)

1. Allhenn D, Boushehri MA, Lamprecht A. 2012. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm 436: 299-310.
2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
3. Blakeley J. 2008. Drug delivery to brain tumors. Curr Neurol Neurosci Rep 8: 235-241.
4. Boccaccio C, Comoglio PM. 2006. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637-645.
5. Boccaccio C, Comoglio PM. 2013. TheMEToncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res 73: 3193-3199.
6. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
7. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, et al. 2012. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 14: 868-879.
8. Celiku O, Johnson S, Zhao S, Camphausen K, Shankavaram U. 2014. Visualizing molecular profiles of glioblastoma with GBM-BioDP. PLoS One 9: e101239.
9. Crowley RW, Pouratian N, Sheehan JP. 2006. Gamma knife surgery for glioblastoma multiforme. Neurosurg Focus 20: E17.
10. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD. 2007. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 107: 610-616.
11. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et al. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26: 756-784.
12. Frens G. 1973. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nat Phys Sci 241: 20-22.
13. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. 2009. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 131: 2072-2073.
14. Golestaneh N, Mishra B. 2005. TGF-β, neuronal stem cells and glioblastoma. Oncogene 24: 5722-5730.
15. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. 2012. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One 7: e51056.
16. Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. 2013. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One 8: e55502.
17. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. 2007. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci 104: 12867-12872.
18. Hui AB, Lin A, XuW, Waldron L, Perez-Ordonez B, Weinreb I, Shi W, Bruce J, Huang SH, O'Sullivan B, et al. 2013. Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res 19: 2154-2162.
19. Huse JT, Holland EC. 2009. Yin and yang: cancer-implicated miRNAs that have it both ways. Cell Cycle 8: 3611-3612.
20. Iorio MV, Croce CM. 2009. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856.
21. Iorio MV, Croce CM. 2012. Causes and consequences of microRNA dysregulation. Cancer J 18: 215-222.
22. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, et al. 2013. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 5: 209ra152.
23. Kim VN. 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385.
24. Kim TM, HuangW, Park R, Park PJ, Johnson MD. 2011. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71: 3387-3399.
25. Kloosterman WP, Plasterk RH. 2006. The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450.
26. Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, Tang H. 2012. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J 279: 1252-1260.
27. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al. 2009. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
28. Li P, Sheng C, Huang L, Zhang H, Cheng Z, Zhu Q. 2014. MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res 16: 473.
29. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, Hernando E, Wei JJ. 2012. MiR-182 overexpression in tumourigenesis of highgrade serous ovarian carcinoma. J Pathol 228: 204-215.
30. Liu R, Li J, Teng Z, Zhang Z, Xu Y. 2013. Overexpressed micro-RNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One 8: e68982.
31. Massich MD, Giljohann DA, Seferos DS, Ludlow LE, Horvath CM, Mirkin CA. 2009. Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates. Mol Pharm 6: 1934-1940.
32. Nana-Sinkam SP, Croce CM. 2013. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93: 98-104.
33. Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Noort PI, Prevost GP, Schaapveld RQ, et al. 2012. A functional screen identifies specific micro-RNAs capable of inhibiting human melanoma cell viability. PLoS One 7: e43569.
34. Puzio-Kuter AM, Levine AJ. 2009. Stem cell biology meets p53. Nat Biotechnol 27: 914-915.
35. Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS. 2013. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer 133: 544-555.
36. Rodgers JT, King KY, Brett JO, Cromie MJ, Charville GW, Maguire KK, Brunson C, Mastey N, Liu L, Tsai CR, et al. 2014. mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature 510: 393-396.
37. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, et al. 2009. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401.
38. Seferos DS, Prigodich AE, Giljohann DA, Patel PC, Mirkin CA. 2009. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano Lett 9: 308-311.
39. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al. 2009. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci 106: 1814-1819.
40. Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, Agius P, Huse JT, Holland EC, Leslie CS. 2012. Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol 8: 605.
41. Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, et al. 2012. TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest 122: 3563-3578.
42. Srikanth M, Das S, Berns EJ, Kim J, Stupp SI, Kessler JA. 2013. Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition. Neuro Oncol 15: 319-329.
43. Stegh AH, De Pinho RA. 2011. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 10: 33-38.
44. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, et al. 2007. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21: 98-111.
45. Stegh AH, Chin L, Louis DN, De Pinho RA. 2008a. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 7: 2833-2839.
46. Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, Depinho RA. 2008b. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci 105: 10703-10708.
47. Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, Protopopov A, Chin L, Depinho RA. 2010. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 24: 2194-2204.
48. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
49. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
50. Tang H, Wang Z, Liu Q, Liu X, WuM, Li G. 2014. Disturbing miR-182 and-381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. PLoS One 9: e84146.
51. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
52. Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, Sengupta S, Archer T, Remke M, Bai AH, et al. 2012. Pleiotropic effects of miR-183∼96∼182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol 123: 539-552.
53. Weston MD, Pierce ML, Jensen-Smith HC, Fritzsch B, Rocha-Sanchez S, Beisel KW, Soukup GA. 2011. MicroRNA-183 family expression in hair cell development and requirement of microRNAs for hair cell maintenance and survival. Dev Dyn 240: 808-819.
54. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D. 2007. Micro-RNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem 282: 25053-25066.
55. Xu X, Wu J, Li S, Hu Z, Zhu Y, Liang Z, Wang X, Lin Y, Mao Y, Chen H, et al. 2014. Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway. Mol Cancer 13: 109.
56. Yan D, Dong XD, Chen X, Yao S, Wang L, Wang C, Hu DN, Qu J, Tu L. 2012. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One 7: e40967.
57. Yang H, Tang Y, Guo W, Du Y, Wang Y, Li P, Zang W, Yin X, Wang H, Chu H, et al. 2014. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. Tumour Biol 35: 6557-6565.